Tasly Pharmaceutical Group Co Ltd (600535):企業の財務・戦略的SWOT分析

◆英語タイトル:Tasly Pharmaceutical Group Co Ltd (600535) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C12930
◆発行会社(調査会社):GlobalData
◆発行日:2019年1月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Tasly Pharmaceutical Group Co Ltd (600535) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Tasly Pharmaceutical Group Co Ltd (Tasly), formerly Tianjin Tasly Pharmaceutical Co., Ltd., manufactures and distributes chemical medicine, biological medicine, healthcare products, traditional Chinese medicine (TCM), functional food and other products. The company’s product line includes herbal medicine, chemical medicine, health product, pharmaceutical substances and active pharmaceutical ingredients (APIs), herbal extract, tea, cosmetics, daily hygiene product series and medical equipment. It markets its products in domestic market through its own sales force and through distributors and subsidiaries in Malaysia, Indonesia, Vietnam, South Korea, Pakistan, Thailand, Istanbul, Botswana, South Africa, Ghana, Kenya, Zambia, Nigeria, Russia, Netherlands, Bahamas and the US. Tasly is headquartered in Tianjin, China.

Tasly Pharmaceutical Group Co Ltd Key Recent Developments

Sep 17,2018: TOPC : Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire : MarketLine - GNW]

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Tasly Pharmaceutical Group Co Ltd – Key Facts 5
Tasly Pharmaceutical Group Co Ltd – Key Employees 6
Tasly Pharmaceutical Group Co Ltd – Major Products and Services 7
Tasly Pharmaceutical Group Co Ltd – History 10
Tasly Pharmaceutical Group Co Ltd – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Joint Venture 12
Section 2 – Company Analysis 13
Company Overview 13
Tasly Pharmaceutical Group Co Ltd – Business Description 14
Tasly Pharmaceutical Group Co Ltd – Corporate Strategy 16
Tasly Pharmaceutical Group Co Ltd – SWOT Analysis 17
SWOT Analysis – Overview 17
Tasly Pharmaceutical Group Co Ltd – Strengths 17
Tasly Pharmaceutical Group Co Ltd – Weaknesses 18
Tasly Pharmaceutical Group Co Ltd – Opportunities 19
Tasly Pharmaceutical Group Co Ltd – Threats 20
Tasly Pharmaceutical Group Co Ltd – Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios – Capital Market Ratios 22
Financial Ratios – Annual Ratios 23
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 29
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 30
Tasly Pharmaceutical Group Co Ltd, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Sep 17, 2018: TOPC : Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire : MarketLine - GNW] 32
Section 6 – Appendix 33
Methodology 33
Ratio Definitions 33
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Tasly Pharmaceutical Group Co Ltd, Key Facts 5
Tasly Pharmaceutical Group Co Ltd, Key Employees 6
Tasly Pharmaceutical Group Co Ltd, Major Products and Services 7
Tasly Pharmaceutical Group Co Ltd, History 10
Tasly Pharmaceutical Group Co Ltd, Subsidiaries 12
Tasly Pharmaceutical Group Co Ltd, Joint Venture 12
Tasly Pharmaceutical Group Co Ltd, Key Competitors 21
Tasly Pharmaceutical Group Co Ltd, Ratios based on current share price 22
Tasly Pharmaceutical Group Co Ltd, Annual Ratios 23
Tasly Pharmaceutical Group Co Ltd, Annual Ratios (Cont...1) 24
Tasly Pharmaceutical Group Co Ltd, Annual Ratios (Cont...2) 25
Tasly Pharmaceutical Group Co Ltd, Interim Ratios 27
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 29
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 30
Tasly Pharmaceutical Group Co Ltd, Recent Deals Summary 31
Currency Codes 33
Capital Market Ratios 33
Equity Ratios 34
Profitability Ratios 34
Cost Ratios 35
Liquidity Ratios 35
Leverage Ratios 36
Efficiency Ratios 36

List of Figures
Tasly Pharmaceutical Group Co Ltd, Performance Chart (2013 - 2017) 26
Tasly Pharmaceutical Group Co Ltd, Ratio Charts 28
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 29
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019 30

★海外企業調査レポート[Tasly Pharmaceutical Group Co Ltd (600535):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Maersk Line AS:企業の戦略的SWOT分析
    Maersk Line AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • PNM Resources Inc (PNM):企業の財務・戦略的SWOT分析
    PNM Resources Inc (PNM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Mitsubishi Paper Mills Ltd (38640):企業の財務・戦略的SWOT分析
    Mitsubishi Paper Mills Ltd (38640) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Cielo Wind Power LP:企業の戦略的SWOT分析
    Cielo Wind Power LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Cyclacel Pharmaceuticals Inc (CYCC):製薬・医療:M&Aディール及び事業提携情報
    Summary Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, selicicli …
  • Ezaki Glico Co Ltd:企業の戦略・SWOT・財務情報
    Ezaki Glico Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Ezaki Glico Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cott Corporation:企業の戦略・SWOT・財務情報
    Cott Corporation - Strategy, SWOT and Corporate Finance Report Summary Cott Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Southern Company Gas:企業の戦略的SWOT分析
    Southern Company Gas - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Abu Dhabi National Energy Co (TAQA):石油・ガス:M&Aディール及び事業提携情報
    Summary Abu Dhabi National Energy Company (TAQA), a subsidiary of government-owned Abu Dhabi Water and Electricity Authority, is an energy and water company. It undertakes power generation; exploration, development, production and storage of oil and gas; pipelines and gas storage; and water desalina …
  • TTEC Holdings Inc.:企業の戦略・SWOT・財務情報
    TTEC Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary TTEC Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Carl Zeiss Meditec AG (AFX):企業の財務・戦略的SWOT分析
    Carl Zeiss Meditec AG (AFX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Calypso Biotech SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Calypso Biotech SA (Calypso) is a biopharmaceutical company that develops antibody therapies. The company provides pipeline products such as CALY-0001 and CALY-0002. Its CALY-0001 therapeutic antibody is used in the treatment of Crohn’s disease; and CALY-0002 a humanized monoclonal antibody …
  • JHL Biotech Inc:医療機器:M&Aディール及び事業提携情報
    Summary JHL Biotech Inc (JHL Biotech) is a biologic medicines provider. The company offers cell line construction, process development, manufacturing, quality and regulatory services. It offers products such as biosimilar rituximab, biosimilar dornase alfa, biosimilar bevacizumab, biosimilar trastuz …
  • Devon Energy Corporation:企業の戦略・SWOT・財務情報
    Devon Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Devon Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Honda Motor Co Ltd (7267):企業の財務・戦略的SWOT分析
    Honda Motor Co Ltd (7267) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Otsuka Pharmaceutical Co., Ltd.:企業のM&A・事業提携・投資動向
    Otsuka Pharmaceutical Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Otsuka Pharmaceutical Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • ResApp Health Ltd (RAP):企業の製品パイプライン分析
    Summary ResApp Health Ltd (ResApp) formerly, Narhex Life Sciences Limited is a digital health company that develops smartphone applications for the diagnosis and management of respiratory disease. It's digital healthcare solutions assist doctors and patients to diagnose and manage respiratory diseas …
  • Chiome Bioscience Inc (4583):製薬・医療:M&Aディール及び事業提携情報
    Summary Chiome Bioscience Inc (Chiome Bioscience) is a healthcare service company that provides research and development of therapies. The company research and develops antibody drugs for the treatment of autoimmune and inflammatory diseases. Its ADLib system is a monoclonal antibody generating syst …
  • Saertex GmbH & Co KG:企業の戦略的SWOT分析
    Saertex GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Snyder’s-Lance, Inc.:戦略・SWOT・企業財務分析
    Snyder's-Lance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Snyder's-Lance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆